BX-795

Catalog No.S1274

Molecular Weight(MW): 591.47

BX795 is a potent and specific PDK1 inhibitor with IC50 of 6 nM, 140- and 1600-fold more selective for PDK1 than PKA and PKC in cell-free assays, respectively. Meanwhile, in comparison to GSK3β more than 100-fold selectivity observed for PDK1.

Cited by 10 Publications

Nature, 2019, 567(7747):262-266

PubMed: 30842662 ( click the link to review the publication )

Cell, 2019, 176(6):1447-1460

PubMed: 30799039 ( click the link to review the publication )

J Thromb Haemost, 2018, 16(6):1211-1225

PubMed: 29575487 ( click the link to review the publication )

J Immunol, 2016, 196(5):2272-82

PubMed: 26826240 ( click the link to review the publication )

PLoS One, 2016, 11(5):e0155052

PubMed: 27148873 ( click the link to review the publication )

J Biomol Screen, 2016, 10.1177/1087057116656314

PubMed: 27358388 ( click the link to review the publication )

Proc Natl Acad Sci USA, 2014, 111(49):17438-43

PubMed: 25326420 ( click the link to review the publication )

FEBS J, 2014, 281(17):3816-27

PubMed: 25040165 ( click the link to review the publication )

Virology, 2014, 450-451:182-95

PubMed: 24503081 ( click the link to review the publication )

PLoS One, 2014, 9(11):e112014

PubMed: 25390891 ( click the link to review the publication )

4 Customer Reviews

Induction of basal p62 Ser403 phosphorylation in ULK1/2-deﬁcient MEF was suppressed by BX-795, an inhibitor of TBK1. WT ( Ulk1 +/+/Ulk2 +/+) and Ulk1 -/- /Ulk2 -/-(KO) MEF were treated with NaCl/Pi (Con) or 10 uM BX-795 for 6 h, and subjected to immunoblotting with indicated antibodies.

FEBS J 2014 281(17), 3816-27. BX-795 purchased from Selleck.

Virology 2014 450-451, 182-95. BX-795 purchased from Selleck.
(A) Washed human platelets were untreated or pretreated with the PDK1 inhibitor BX-795 (1 μM) for 5 min, and this was followed by stimulation with 2-methylthio-ADP (2MeSADP) (50 nM) under stirring for 5 min. Western blots were then probed for phosphorylated Akt (Thr308), Akt (Ser473), glycogen synthase kinase 3b (GSK3b) (Ser9), mitogen-activated protein kinase kinase 1/2 (MEK1/2) (Ser217/221), extracellular signal-regulated kinase 1/2 (ERK1/2) (Thr202/Tyr204), and cytosolic phospholipase A2 (cPLA2) (Ser505). The western blots shown are representative of three independent experiments.

J Thromb Haemost, 2018, 16(6):1211-1225. BX-795 purchased from Selleck.

Western blot analysis of pPRAS40 (T246), pS6 (S240/S244), and pS6 (S235/S236) proteins in (A) HeyA8 cells and (B) SKOV3 cells treated with 3.33 μM or 10 μM inhibitors (BX795 or CCT128930) in three-dimensional cell culture for 24 hours. Ten percent fetal bovine serum was used in A and B.

PLoS One, 2016, 11(5):e0155052. . BX-795 purchased from Selleck.

Purity & Quality Control

Choose Selective PDK Inhibitors

Biological Activity

Description

Targets

PDK-1 ^[1] (Cell-free assay)	c-Kit ^[1] (Cell-free assay)	CDK2/CyclinE ^[1] (Cell-free assay)	Chk1 ^[1] (Cell-free assay)
6 nM	320 nM	430 nM	510 nM

In vitro

BX-795 effectively blocks PDK1 activity in PC-3 cells, as shown by their ability to block phosphorylation of S6K1, Akt, PKCδ, and GSK3β. BX-795 potently inhibits tumor cell growth on plastic with IC50 of 1.6, 1.4, and 1.9 μM for MDA-468, HCT-116 and MiaPaca cells, respectively. In soft agar, BX-795 displays higher growth inhibition with IC50 of 0.72, and 0.25 μM for MDA-468, and PC-3 cells, respectively. ^[1] In addition, BX-795, as an inhibitor of the TBK1/IKKɛ, blocks TBK1- and IKKε-mediated activation of IRF3 and production of IFN-β. ^[2] In platelet physiological responses, BX795 produces inhibitory effect on 2-MeSADP-induced or collagen-induced aggregation, ATP secretion and thromboxane generation. ^[3]

Cell Data

Cell Lines	Assay Type	Incubation Time	Activity Description	PMID
human MV-4-11 cell	NInRPHNIem:5dHigbY5pcWKrdHnvckBie3OjeR?=		NIfQPW9KdmirYnn0bY9vKG:oIHj1cYFvKE2YLUStNVEh[2WubDDndo94fGhiaX6gZUBk\WyuII\pZYJqdGm2eTDhd5NigSxiSVO1NF0{Pi56IH7N	NH;hNlBUSU6JRWK=
KRX cells	M13yPGZ2dmO2aX;uJIF{e2G7	Ml\WO{BucW6\|	M4jQbmlvcGmkaYTpc44hd2ZiU2XNU{11[WepZXSgWWxMOSBqdX7rco94diCxcnnnbY4qKGurbnHz[UBld22jaX6g[ZhxemW\|c3XkJIlvKEuUWDDj[YxteyC3c3nu[{BcOzKSXT3nZY1u[S2DVGCgZY5lKG27ZXzpckBj[XOrYzDwdo91\WmwIIP1ZpN1emG2ZTDpcoN2[mG2ZXSg[o9zKDdibXnudy=>	NFP3NJEzPjJ5NU[4NS=>
human NKM-1 cell	NELwcopIem:5dHigbY5pcWKrdHnvckBie3OjeR?=		MVTJcohq[mm2aX;uJI9nKGi3bXHuJG5MVS1zIHPlcIwh\3Kxd4ToJIlvKGFiY3XscEB3cWGkaXzpeJkh[XO\|YYmsJGlEPTB;MD6zOlE6PCEQvF2=	MYnTRW5ITVJ?
human P30-OHK cell	MWrHdo94fGhiaX7obYJqfGmxbjDhd5NigQ>?		NVX0NHFkUW6qaXLpeIlwdiCxZjDoeY1idiCSM{CtU2hMKGOnbHyg[5Jwf3SqIHnuJIEh[2WubDD2bYFjcWyrdImsJGlEPTB;MD60PVY2KM7:TR?=	MonOV2FPT0WU
human YH-13 cell	NXvjV\|RCT3Kxd4ToJIlvcGmkaYTpc44h[XO\|YYm=		Ml2wTY5pcWKrdHnvckBw\iCqdX3hckB[UC1zMzDj[YxtKGe{b4f0bEBqdiCjIHPlcIwhfmmjYnnsbZR6KGG\|c3H5MEBKSzVyPUCuOlI5QDhizszN	MV7TRW5ITVJ?
human LXF-289 cell	MYnHdo94fGhiaX7obYJqfGmxbjDhd5NigQ>?		MYDJcohq[mm2aX;uJI9nKGi3bXHuJGxZTi1{OEmgZ4VtdCCpcn;3eIghcW5iYTDj[YxtKH[rYXLpcIl1gSCjc4PhfU4hUUN3ME2wMlY2Pjl\|IN88US=>	NEPlSlBUSU6JRWK=
human BE-13 cell	NYT2VnRzT3Kxd4ToJIlvcGmkaYTpc44h[XO\|YYm=		MnniTY5pcWKrdHnvckBw\iCqdX3hckBDTS1zMzDj[YxtKGe{b4f0bEBqdiCjIHPlcIwhfmmjYnnsbZR6KGG\|c3H5MEBKSzVyPUCuO\|A1PzdizszN	M{TTZ3NCVkeHUh?=
human RS4-11 cell	Mn:5S5Jwf3SqIHnubIljcXSrb36gZZN{[Xl?		M17CV2lvcGmkaYTpc44hd2ZiaIXtZY4hWlN2LUGxJINmdGxiZ4Lve5RpKGmwIHGgZ4VtdCC4aXHibYxqfHliYYPzZZktKEmFNUC9NE44OjV7NDFOwG0>	M4ezdnNCVkeHUh?=
human A3-KAW cell	NGXHSm5Iem:5dHigbY5pcWKrdHnvckBie3OjeR?=		Mmn3TY5pcWKrdHnvckBw\iCqdX3hckBCOy2NQWegZ4VtdCCpcn;3eIghcW5iYTDj[YxtKH[rYXLpcIl1gSCjc4PhfUwhUUN3ME2wMlc{ODV3IN88US=>	MUnTRW5ITVJ?
human PA-1 cell	NHrIVGJIem:5dHigbY5pcWKrdHnvckBie3OjeR?=		Ml7hTY5pcWKrdHnvckBw\iCqdX3hckBRSS1zIHPlcIwh\3Kxd4ToJIlvKGFiY3XscEB3cWGkaXzpeJkh[XO\|YYmsJGlEPTB;MD64NFQzOiEQvF2=	M1\PZnNCVkeHUh?=
human ES7 cell	NY\ubGRZT3Kxd4ToJIlvcGmkaYTpc44h[XO\|YYm=		MYPJcohq[mm2aX;uJI9nKGi3bXHuJGVUPyClZXzsJIdzd3e2aDDpckBiKGOnbHygeoli[mmuaYT5JIF{e2G7LDDJR\|UxRTBwOEO1OlYh\|ryP	MnW5V2FPT0WU
human ES8 cell	MWPHdo94fGhiaX7obYJqfGmxbjDhd5NigQ>?		NUO5d\|lUUW6qaXLpeIlwdiCxZjDoeY1idiCHU{igZ4VtdCCpcn;3eIghcW5iYTDj[YxtKH[rYXLpcIl1gSCjc4PhfUwhUUN3ME2wMlg1OzN4IN88US=>	MXrTRW5ITVJ?
human SW982 cell	MYrHdo94fGhiaX7obYJqfGmxbjDhd5NigQ>?		NG\ZenpKdmirYnn0bY9vKG:oIHj1cYFvKFOZOUiyJINmdGxiZ4Lve5RpKGmwIHGgZ4VtdCC4aXHibYxqfHliYYPzZZktKEmFNUC9NE46PTF{NDFOwG0>	MoHMV2FPT0WU
human VA-ES-BJ cell	NETGbohIem:5dHigbY5pcWKrdHnvckBie3OjeR?=		MknLTY5pcWKrdHnvckBw\iCqdX3hckBXSS2HUz3CTkBk\WyuIHfyc5d1cCCrbjDhJINmdGxidnnhZoltcXS7IHHzd4F6NCCLQ{WwQVAvQTh2Nkeg{txO	MoLwV2FPT0WU
human 697 cell	NHfJOYxIem:5dHigbY5pcWKrdHnvckBie3OjeR?=		NUftTXpVUW6qaXLpeIlwdiCxZjDoeY1idiB4OUegZ4VtdCCpcn;3eIghcW5iYTDj[YxtKH[rYXLpcIl1gSCjc4PhfUwhUUN3ME2xMlAyPjJ\|IN88US=>	M1;mS3NCVkeHUh?=
human MOLT-4 cell	Moj0S5Jwf3SqIHnubIljcXSrb36gZZN{[Xl?		NHrwemJKdmirYnn0bY9vKG:oIHj1cYFvKE2RTGStOEBk\WyuIHfyc5d1cCCrbjDhJINmdGxidnnhZoltcXS7IHHzd4F6NCCLQ{WwQVEvODN{NESg{txO	M2\oSnNCVkeHUh?=
human D-283MED cell	NGnlXmVIem:5dHigbY5pcWKrdHnvckBie3OjeR?=		MmDETY5pcWKrdHnvckBw\iCqdX3hckBFNTJ6M13FSEBk\WyuIHfyc5d1cCCrbjDhJINmdGxidnnhZoltcXS7IHHzd4F6NCCLQ{WwQVEvODN7NEig{rxu	M4nJVHNCVkeHUh?=
human ALL-PO cell	M2K1Vmdzd3e2aDDpcohq[mm2aX;uJIF{e2G7		Mn7zTY5pcWKrdHnvckBw\iCqdX3hckBCVExvUF:gZ4VtdCCpcn;3eIghcW5iYTDj[YxtKH[rYXLpcIl1gSCjc4PhfUwhUUN3ME2xMlA3ODd\|IN88US=>	NGn2cmxUSU6JRWK=
human NB14 cell	MYnHdo94fGhiaX7obYJqfGmxbjDhd5NigQ>?		MUXJcohq[mm2aX;uJI9nKGi3bXHuJG5DOTRiY3XscEBoem:5dHigbY4h[SClZXzsJJZq[WKrbHn0fUBie3OjeTygTWM2OD1zLkC2NFgyKM7:TR?=	NVT4[5JGW0GQR1XS
human NTERA-S-cl-D1 cell	NVnUboFjT3Kxd4ToJIlvcGmkaYTpc44h[XO\|YYm=		NHrqW5hKdmirYnn0bY9vKG:oIHj1cYFvKE6WRWLBMXMu[2xvREGgZ4VtdCCpcn;3eIghcW5iYTDj[YxtKH[rYXLpcIl1gSCjc4PhfUwhUUN3ME2xMlA4Pzd3IN88US=>	NXLGbWsxW0GQR1XS
human BFTC-905 cell	M1jDS2dzd3e2aDDpcohq[mm2aX;uJIF{e2G7		MUTJcohq[mm2aX;uJI9nKGi3bXHuJGJHXENvOUC1JINmdGxiZ4Lve5RpKGmwIHGgZ4VtdCC4aXHibYxqfHliYYPzZZktKEmFNUC9NU4xQDFyMTFOwG0>	MYjTRW5ITVJ?
human H4 cell	Mmr0S5Jwf3SqIHnubIljcXSrb36gZZN{[Xl?		MVHJcohq[mm2aX;uJI9nKGi3bXHuJGg1KGOnbHyg[5Jwf3SqIHnuJIEh[2WubDD2bYFjcWyrdImgZZN{[XluIFnDOVA:OS5zMEKwNUDPxE1?	M2PzdnNCVkeHUh?=
human CHP-212 cell	NHrwfWtIem:5dHigbY5pcWKrdHnvckBie3OjeR?=		NXnoZnBRUW6qaXLpeIlwdiCxZjDoeY1idiCFSGCtNlEzKGOnbHyg[5Jwf3SqIHnuJIEh[2WubDD2bYFjcWyrdImgZZN{[XluIFnDOVA:OS5zNECzO{DPxE1?	M3TKOXNCVkeHUh?=
human A204 cell	NFrqbJFIem:5dHigbY5pcWKrdHnvckBie3OjeR?=		M3[2NWlvcGmkaYTpc44hd2ZiaIXtZY4hSTJyNDDj[YxtKGe{b4f0bEBqdiCjIHPlcIwhfmmjYnnsbZR6KGG\|c3H5MEBKSzVyPUGuNVU1PjdizszN	MVLTRW5ITVJ?
human NB69 cell	M3\4bGdzd3e2aDDpcohq[mm2aX;uJIF{e2G7		MnL4TY5pcWKrdHnvckBw\iCqdX3hckBPSjZ7IHPlcIwh\3Kxd4ToJIlvKGFiY3XscEB3cWGkaXzpeJkh[XO\|YYmsJGlEPTB;MT6xOVg3PSEQvF2=	NHLodnBUSU6JRWK=
human P12-ICHIKAWA cell	NIjPWWZIem:5dHigbY5pcWKrdHnvckBie3OjeR?=		M2fCbGlvcGmkaYTpc44hd2ZiaIXtZY4hWDF{LVnDTGlMSVeDIHPlcIwh\3Kxd4ToJIlvKGFiY3XscEB3cWGkaXzpeJkh[XO\|YYmsJGlEPTB;MT6xPFE4OSEQvF2=	MXzTRW5ITVJ?
human L-363 cell	M3nnVGdzd3e2aDDpcohq[mm2aX;uJIF{e2G7		M4LmbGlvcGmkaYTpc44hd2ZiaIXtZY4hVC1\|NkOgZ4VtdCCpcn;3eIghcW5iYTDj[YxtKH[rYXLpcIl1gSCjc4PhfUwhUUN3ME2xMlE5OTl5IN88US=>	NFHqWYlUSU6JRWK=
human ES5 cell	M3m5Z2dzd3e2aDDpcohq[mm2aX;uJIF{e2G7		M13ZZmlvcGmkaYTpc44hd2ZiaIXtZY4hTVN3IHPlcIwh\3Kxd4ToJIlvKGFiY3XscEB3cWGkaXzpeJkh[XO\|YYmsJGlEPTB;MT6xPVM2PCEQvF2=	MX3TRW5ITVJ?
human CAL-51 cell	MVvHdo94fGhiaX7obYJqfGmxbjDhd5NigQ>?		M3TWVmlvcGmkaYTpc44hd2ZiaIXtZY4hS0GOLUWxJINmdGxiZ4Lve5RpKGmwIHGgZ4VtdCC4aXHibYxqfHliYYPzZZktKEmFNUC9NU4zOjF3NjFOwG0>	NEnSeZRUSU6JRWK=
human NBsusSR cell	MmXTS5Jwf3SqIHnubIljcXSrb36gZZN{[Xl?		Mk\BTY5pcWKrdHnvckBw\iCqdX3hckBPSnO3c2PSJINmdGxiZ4Lve5RpKGmwIHGgZ4VtdCC4aXHibYxqfHliYYPzZZktKEmFNUC9NU4zPDV5ODFOwG0>	NVHTbHpMW0GQR1XS
human HOP-92 cell	NVrCR3JjT3Kxd4ToJIlvcGmkaYTpc44h[XO\|YYm=		MoH3TY5pcWKrdHnvckBw\iCqdX3hckBJV1BvOUKgZ4VtdCCpcn;3eIghcW5iYTDj[YxtKH[rYXLpcIl1gSCjc4PhfUwhUUN3ME2xMlI4Ojl\|IN88US=>	M3nPUHNCVkeHUh?=
human DU-4475 cell	NVTqelJWT3Kxd4ToJIlvcGmkaYTpc44h[XO\|YYm=		NXLjdINjUW6qaXLpeIlwdiCxZjDoeY1idiCGVT20OFc2KGOnbHyg[5Jwf3SqIHnuJIEh[2WubDD2bYFjcWyrdImgZZN{[XluIFnDOVA:OS5{OUK0OUDPxE1?	NGrSRYlUSU6JRWK=
human LB1047-RCC cell	M2WzSGdzd3e2aDDpcohq[mm2aX;uJIF{e2G7		NH7GS\|VKdmirYnn0bY9vKG:oIHj1cYFvKEyEMUC0O{1TS0NiY3XscEBoem:5dHigbY4h[SClZXzsJJZq[WKrbHn0fUBie3OjeTygTWM2OD1zLkK5NlgyKM7:TR?=	MYrTRW5ITVJ?
human D-566MG cell	MXzHdo94fGhiaX7obYJqfGmxbjDhd5NigQ>?		M3jSNmlvcGmkaYTpc44hd2ZiaIXtZY4hTC13Nk\NS{Bk\WyuIHfyc5d1cCCrbjDhJINmdGxidnnhZoltcXS7IHHzd4F6NCCLQ{WwQVEvOzB2NEig{txO	MnrXV2FPT0WU
human A375 cell	MUXHdo94fGhiaX7obYJqfGmxbjDhd5NigQ>?		NX7ObWtNUW6qaXLpeIlwdiCxZjDoeY1idiCDM{e1JINmdGxiZ4Lve5RpKGmwIHGgZ4VtdCC4aXHibYxqfHliYYPzZZktKEmFNUC9NU4{ODh3ODFOwG0>	Mmi1V2FPT0WU
human ATN-1 cell	MonHS5Jwf3SqIHnubIljcXSrb36gZZN{[Xl?		NHXCO5NKdmirYnn0bY9vKG:oIHj1cYFvKEGWTj2xJINmdGxiZ4Lve5RpKGmwIHGgZ4VtdCC4aXHibYxqfHliYYPzZZktKEmFNUC9NU4{PzF6NTFOwG0>	MXLTRW5ITVJ?
human M059J cell	NHPNdWRIem:5dHigbY5pcWKrdHnvckBie3OjeR?=		NHjwV5hKdmirYnn0bY9vKG:oIHj1cYFvKE1yNUnKJINmdGxiZ4Lve5RpKGmwIHGgZ4VtdCC4aXHibYxqfHliYYPzZZktKEmFNUC9NU4{PzZ3MjFOwG0>	MV;TRW5ITVJ?
human HSC-3 cell	MlTRS5Jwf3SqIHnubIljcXSrb36gZZN{[Xl?		NF\NOmxKdmirYnn0bY9vKG:oIHj1cYFvKEiVQz2zJINmdGxiZ4Lve5RpKGmwIHGgZ4VtdCC4aXHibYxqfHliYYPzZZktKEmFNUC9NU41PDJyODFOwG0>	MnWzV2FPT0WU
human DOHH-2 cell	MX3Hdo94fGhiaX7obYJqfGmxbjDhd5NigQ>?		M{jPbmlvcGmkaYTpc44hd2ZiaIXtZY4hTE:KSD2yJINmdGxiZ4Lve5RpKGmwIHGgZ4VtdCC4aXHibYxqfHliYYPzZZktKEmFNUC9NU41PThzNDFOwG0>	NHzj[HdUSU6JRWK=
human G-402 cell	MmLOS5Jwf3SqIHnubIljcXSrb36gZZN{[Xl?		M1;0eGlvcGmkaYTpc44hd2ZiaIXtZY4hTy12MEKgZ4VtdCCpcn;3eIghcW5iYTDj[YxtKH[rYXLpcIl1gSCjc4PhfUwhUUN3ME2xMlQ3PTJ3IN88US=>	M4L0eXNCVkeHUh?=
human LC-2-ad cell	MlzlS5Jwf3SqIHnubIljcXSrb36gZZN{[Xl?		MkHUTY5pcWKrdHnvckBw\iCqdX3hckBNSy1{LXHkJINmdGxiZ4Lve5RpKGmwIHGgZ4VtdCC4aXHibYxqfHliYYPzZZktKEmFNUC9NU41PzF\|MjFOwG0>	NIW4[Y1USU6JRWK=
human LOXIMVI cell	MUDHdo94fGhiaX7obYJqfGmxbjDhd5NigQ>?		NHTtWWlKdmirYnn0bY9vKG:oIHj1cYFvKEyRWFnNWmkh[2WubDDndo94fGhiaX6gZUBk\WyuII\pZYJqdGm2eTDhd5NigSxiSVO1NF0yNjVyNUWyJO69VQ>?	NX\SfZNmW0GQR1XS
human DK-MG cell	M33pOmdzd3e2aDDpcohq[mm2aX;uJIF{e2G7		Mlj3TY5pcWKrdHnvckBw\iCqdX3hckBFUy2PRzDj[YxtKGe{b4f0bEBqdiCjIHPlcIwhfmmjYnnsbZR6KGG\|c3H5MEBKSzVyPUGuOVczQThizszN	M{HTUXNCVkeHUh?=
human HOS cell	NELKb5RIem:5dHigbY5pcWKrdHnvckBie3OjeR?=		NX\yb3VUUW6qaXLpeIlwdiCxZjDoeY1idiCKT2OgZ4VtdCCpcn;3eIghcW5iYTDj[YxtKH[rYXLpcIl1gSCjc4PhfUwhUUN3ME2xMlU4OzB7IN88US=>	MXnTRW5ITVJ?
human BHT-101 cell	NV:4bI5RT3Kxd4ToJIlvcGmkaYTpc44h[XO\|YYm=		MkLTTY5pcWKrdHnvckBw\iCqdX3hckBDUFRvMUCxJINmdGxiZ4Lve5RpKGmwIHGgZ4VtdCC4aXHibYxqfHliYYPzZZktKEmFNUC9NU42Pzh5NzFOwG0>	MXLTRW5ITVJ?
human U-2-OS cell	NXjXT3ZET3Kxd4ToJIlvcGmkaYTpc44h[XO\|YYm=		M4XxPWlvcGmkaYTpc44hd2ZiaIXtZY4hXS1{LV;TJINmdGxiZ4Lve5RpKGmwIHGgZ4VtdCC4aXHibYxqfHliYYPzZZktKEmFNUC9NU42QDhyNjFOwG0>	MWDTRW5ITVJ?
human D-423MG cell	Mn7XS5Jwf3SqIHnubIljcXSrb36gZZN{[Xl?		MmjXTY5pcWKrdHnvckBw\iCqdX3hckBFNTR{M13HJINmdGxiZ4Lve5RpKGmwIHGgZ4VtdCC4aXHibYxqfHliYYPzZZktKEmFNUC9NU43ODhyNjFOwG0>	M3\6WnNCVkeHUh?=
human AN3-CA cell	NXrWPGdOT3Kxd4ToJIlvcGmkaYTpc44h[XO\|YYm=		M{LDbWlvcGmkaYTpc44hd2ZiaIXtZY4hSU5\|LVPBJINmdGxiZ4Lve5RpKGmwIHGgZ4VtdCC4aXHibYxqfHliYYPzZZktKEmFNUC9NU43Ozl7MTFOwG0>	MUDTRW5ITVJ?
human TE-11 cell	NFHtbmxIem:5dHigbY5pcWKrdHnvckBie3OjeR?=		M3zRd2lvcGmkaYTpc44hd2ZiaIXtZY4hXEVvMUGgZ4VtdCCpcn;3eIghcW5iYTDj[YxtKH[rYXLpcIl1gSCjc4PhfUwhUUN3ME2xMlY2OjhizszN	NVftdYhWW0GQR1XS
human SK-NEP-1 cell	Mm[xS5Jwf3SqIHnubIljcXSrb36gZZN{[Xl?		M{HiTWlvcGmkaYTpc44hd2ZiaIXtZY4hW0tvTlXQMVEh[2WubDDndo94fGhiaX6gZUBk\WyuII\pZYJqdGm2eTDhd5NigSxiSVO1NF0yNjZ3M{e2JO69VQ>?	MWfTRW5ITVJ?
human MG-63 cell	MlXSS5Jwf3SqIHnubIljcXSrb36gZZN{[Xl?		NUPnSHNsUW6qaXLpeIlwdiCxZjDoeY1idiCPRz22N{Bk\WyuIHfyc5d1cCCrbjDhJINmdGxidnnhZoltcXS7IHHzd4F6NCCLQ{WwQVEvPjh3Nkeg{txO	NVzIVnNyW0GQR1XS
human RH-1 cell	MXvHdo94fGhiaX7obYJqfGmxbjDhd5NigQ>?		M3r6NGlvcGmkaYTpc44hd2ZiaIXtZY4hWkhvMTDj[YxtKGe{b4f0bEBqdiCjIHPlcIwhfmmjYnnsbZR6KGG\|c3H5MEBKSzVyPUGuO\|AzPzRizszN	NW[5Tld5W0GQR1XS
human MDA-MB-157 cell	MXvHdo94fGhiaX7obYJqfGmxbjDhd5NigQ>?		MkDkTY5pcWKrdHnvckBw\iCqdX3hckBOTEFvTVKtNVU4KGOnbHyg[5Jwf3SqIHnuJIEh[2WubDD2bYFjcWyrdImgZZN{[XluIFnDOVA:OS55MU[3OEDPxE1?	M3\VSXNCVkeHUh?=
human A427 cell	MlGzS5Jwf3SqIHnubIljcXSrb36gZZN{[Xl?		MUfJcohq[mm2aX;uJI9nKGi3bXHuJGE1OjdiY3XscEBoem:5dHigbY4h[SClZXzsJJZq[WKrbHn0fUBie3OjeTygTWM2OD1zLkezOVg6KM7:TR?=	MWfTRW5ITVJ?
human ES1 cell	NVm0T4c2T3Kxd4ToJIlvcGmkaYTpc44h[XO\|YYm=		MonHTY5pcWKrdHnvckBw\iCqdX3hckBGWzFiY3XscEBoem:5dHigbY4h[SClZXzsJJZq[WKrbHn0fUBie3OjeTygTWM2OD1zLke1OFUyKM7:TR?=	NVH3NGNjW0GQR1XS
human C32 cell	NUjlR3hET3Kxd4ToJIlvcGmkaYTpc44h[XO\|YYm=		MW\Jcohq[mm2aX;uJI9nKGi3bXHuJGM{OiClZXzsJIdzd3e2aDDpckBiKGOnbHygeoli[mmuaYT5JIF{e2G7LDDJR\|UxRTFwN{[zPUDPxE1?	NGLEc5ZUSU6JRWK=
human LAMA-84 cell	NHvVemVIem:5dHigbY5pcWKrdHnvckBie3OjeR?=		NUPG[Y1yUW6qaXLpeIlwdiCxZjDoeY1idiCOQV3BMVg1KGOnbHyg[5Jwf3SqIHnuJIEh[2WubDD2bYFjcWyrdImgZZN{[XluIFnDOVA:OS55Nki3NkDPxE1?	MlSxV2FPT0WU
human YKG-1 cell	M4nRWGdzd3e2aDDpcohq[mm2aX;uJIF{e2G7		NUf0Z\|dDUW6qaXLpeIlwdiCxZjDoeY1idiC\S1etNUBk\WyuIHfyc5d1cCCrbjDhJINmdGxidnnhZoltcXS7IHHzd4F6NCCLQ{WwQVEvPzdzMkSg{txO	NF:2bZdUSU6JRWK=
human NCI-H1048 cell	NE\rZnlIem:5dHigbY5pcWKrdHnvckBie3OjeR?=		MWPJcohq[mm2aX;uJI9nKGi3bXHuJG5EUS2KMUC0PEBk\WyuIHfyc5d1cCCrbjDhJINmdGxidnnhZoltcXS7IHHzd4F6NCCLQ{WwQVEvPzh3MEmg{txO	MVXTRW5ITVJ?
human KS-1 cell	M3zHeGdzd3e2aDDpcohq[mm2aX;uJIF{e2G7		NIDHdJFKdmirYnn0bY9vKG:oIHj1cYFvKEuVLUGgZ4VtdCCpcn;3eIghcW5iYTDj[YxtKH[rYXLpcIl1gSCjc4PhfUwhUUN3ME2xMlgzQThizszN	MmX5V2FPT0WU
human JVM-3 cell	M{nSXWdzd3e2aDDpcohq[mm2aX;uJIF{e2G7		MV\Jcohq[mm2aX;uJI9nKGi3bXHuJGpXVS1\|IHPlcIwh\3Kxd4ToJIlvKGFiY3XscEB3cWGkaXzpeJkh[XO\|YYmsJGlEPTB;MT64OlQ6OSEQvF2=	MXTTRW5ITVJ?
human GI-ME-N cell	MkLpS5Jwf3SqIHnubIljcXSrb36gZZN{[Xl?		MWPJcohq[mm2aX;uJI9nKGi3bXHuJGdKNU2HLV6gZ4VtdCCpcn;3eIghcW5iYTDj[YxtKH[rYXLpcIl1gSCjc4PhfUwhUUN3ME2xMlg3PTNizszN	NV3TTZN2W0GQR1XS
human GT3TKB cell	Mor4S5Jwf3SqIHnubIljcXSrb36gZZN{[Xl?		NEPWNVRKdmirYnn0bY9vKG:oIHj1cYFvKEeWM2TLRkBk\WyuIHfyc5d1cCCrbjDhJINmdGxidnnhZoltcXS7IHHzd4F6NCCLQ{WwQVEvQDl4NEKg{txO	MVvTRW5ITVJ?
human CHL-1 cell	NHf6NoxIem:5dHigbY5pcWKrdHnvckBie3OjeR?=		NUH4fmtkUW6qaXLpeIlwdiCxZjDoeY1idiCFSFytNUBk\WyuIHfyc5d1cCCrbjDhJINmdGxidnnhZoltcXS7IHHzd4F6NCCLQ{WwQVEvQTJ\|N{mg{txO	M4LiXnNCVkeHUh?=
human CHP-134 cell	NWn4WmV[T3Kxd4ToJIlvcGmkaYTpc44h[XO\|YYm=		MlHKTY5pcWKrdHnvckBw\iCqdX3hckBEUFBvMUO0JINmdGxiZ4Lve5RpKGmwIHGgZ4VtdCC4aXHibYxqfHliYYPzZZktKEmFNUC9NU46PDR4NzFOwG0>	MonkV2FPT0WU
human 8-MG-BA cell	MlTRS5Jwf3SqIHnubIljcXSrb36gZZN{[Xl?		MVvJcohq[mm2aX;uJI9nKGi3bXHuJFguVUdvQlGgZ4VtdCCpcn;3eIghcW5iYTDj[YxtKH[rYXLpcIl1gSCjc4PhfUwhUUN3ME2xMlk2PzR2IN88US=>	NXLBWJNJW0GQR1XS
human HO-1-N-1 cell	M3PwRmdzd3e2aDDpcohq[mm2aX;uJIF{e2G7		MULJcohq[mm2aX;uJI9nKGi3bXHuJGhQNTFvTj2xJINmdGxiZ4Lve5RpKGmwIHGgZ4VtdCC4aXHibYxqfHliYYPzZZktKEmFNUC9NU46PzFzNzFOwG0>	NX;oVXJLW0GQR1XS
human SW1088 cell	M{j0UGdzd3e2aDDpcohq[mm2aX;uJIF{e2G7		MWnJcohq[mm2aX;uJI9nKGi3bXHuJHNYOTB6ODDj[YxtKGe{b4f0bEBqdiCjIHPlcIwhfmmjYnnsbZR6KGG\|c3H5MEBKSzVyPUGuPVk3PzNizszN	NVPOXZpxW0GQR1XS
human SW48 cell	M3PwWmdzd3e2aDDpcohq[mm2aX;uJIF{e2G7		NHzKVWhKdmirYnn0bY9vKG:oIHj1cYFvKFOZNEigZ4VtdCCpcn;3eIghcW5iYTDj[YxtKH[rYXLpcIl1gSCjc4PhfUwhUUN3ME2yMlAzODZ5IN88US=>	NX[wZYFZW0GQR1XS
human VM-CUB-1 cell	Ml61S5Jwf3SqIHnubIljcXSrb36gZZN{[Xl?		NWDxPZhrUW6qaXLpeIlwdiCxZjDoeY1idiCYTT3DWWIuOSClZXzsJIdzd3e2aDDpckBiKGOnbHygeoli[mmuaYT5JIF{e2G7LDDJR\|UxRTJwMESxNVkh\|ryP	MX\TRW5ITVJ?
human COLO-800 cell	NULkfYYyT3Kxd4ToJIlvcGmkaYTpc44h[XO\|YYm=		MmrPTY5pcWKrdHnvckBw\iCqdX3hckBEV0yRLUiwNEBk\WyuIHfyc5d1cCCrbjDhJINmdGxidnnhZoltcXS7IHHzd4F6NCCLQ{WwQVIvODVzM{[g{txO	Moj0V2FPT0WU
human TI-73 cell	M4jHW2dzd3e2aDDpcohq[mm2aX;uJIF{e2G7		NVTRVm5iUW6qaXLpeIlwdiCxZjDoeY1idiCWST23N{Bk\WyuIHfyc5d1cCCrbjDhJINmdGxidnnhZoltcXS7IHHzd4F6NCCLQ{WwQVIvOTF\|OUmg{txO	M1;HTHNCVkeHUh?=
human HN cell	MXnHdo94fGhiaX7obYJqfGmxbjDhd5NigQ>?		MUjJcohq[mm2aX;uJI9nKGi3bXHuJGhPKGOnbHyg[5Jwf3SqIHnuJIEh[2WubDD2bYFjcWyrdImgZZN{[XluIFnDOVA:Oi5zMkG5PEDPxE1?	MVjTRW5ITVJ?
human DB cell	MnnuS5Jwf3SqIHnubIljcXSrb36gZZN{[Xl?		MV3Jcohq[mm2aX;uJI9nKGi3bXHuJGRDKGOnbHyg[5Jwf3SqIHnuJIEh[2WubDD2bYFjcWyrdImgZZN{[XluIFnDOVA:Oi5zMk[zNUDPxE1?	NH3BT5VUSU6JRWK=
human Ca9-22 cell	MUXHdo94fGhiaX7obYJqfGmxbjDhd5NigQ>?		MkjZTY5pcWKrdHnvckBw\iCqdX3hckBE[TlvMkKgZ4VtdCCpcn;3eIghcW5iYTDj[YxtKH[rYXLpcIl1gSCjc4PhfUwhUUN3ME2yMlEzQDR5IN88US=>	Ml7WV2FPT0WU
human A549 cell	NGPVSVJIem:5dHigbY5pcWKrdHnvckBie3OjeR?=		MoLITY5pcWKrdHnvckBw\iCqdX3hckBCPTR7IHPlcIwh\3Kxd4ToJIlvKGFiY3XscEB3cWGkaXzpeJkh[XO\|YYmsJGlEPTB;Mj6xN\|gxQCEQvF2=	MmfPV2FPT0WU
human KGN cell	NUnGTXp4T3Kxd4ToJIlvcGmkaYTpc44h[XO\|YYm=		MWDJcohq[mm2aX;uJI9nKGi3bXHuJGtIViClZXzsJIdzd3e2aDDpckBiKGOnbHygeoli[mmuaYT5JIF{e2G7LDDJR\|UxRTJwMkK1PVUh\|ryP	NG\5N3JUSU6JRWK=
human BCPAP cell	M1\FS2dzd3e2aDDpcohq[mm2aX;uJIF{e2G7		MoX1TY5pcWKrdHnvckBw\iCqdX3hckBDS1CDUDDj[YxtKGe{b4f0bEBqdiCjIHPlcIwhfmmjYnnsbZR6KGG\|c3H5MEBKSzVyPUKuNlMyPThizszN	MmrQV2FPT0WU
human Ramos-2G6-4C10 cell	NH2yRnZIem:5dHigbY5pcWKrdHnvckBie3OjeR?=		M13UR2lvcGmkaYTpc44hd2ZiaIXtZY4hWmGvb4OtNmc3NTSFMUCgZ4VtdCCpcn;3eIghcW5iYTDj[YxtKH[rYXLpcIl1gSCjc4PhfUwhUUN3ME2yMlI{PzV7IN88US=>	M3\HUXNCVkeHUh?=
human OVCAR-5 cell	NUPQRWc4T3Kxd4ToJIlvcGmkaYTpc44h[XO\|YYm=		Mk\UTY5pcWKrdHnvckBw\iCqdX3hckBQXkODUj21JINmdGxiZ4Lve5RpKGmwIHGgZ4VtdCC4aXHibYxqfHliYYPzZZktKEmFNUC9Nk4zPzd\|NDFOwG0>	NGTNeopUSU6JRWK=
human KG-1 cell	Moq4S5Jwf3SqIHnubIljcXSrb36gZZN{[Xl?		MnmyTY5pcWKrdHnvckBw\iCqdX3hckBMTy1zIHPlcIwh\3Kxd4ToJIlvKGFiY3XscEB3cWGkaXzpeJkh[XO\|YYmsJGlEPTB;Mj6yO\|c6OiEQvF2=	MX3TRW5ITVJ?
human CAKI-1 cell	NI\PUWZIem:5dHigbY5pcWKrdHnvckBie3OjeR?=		NEfkd3NKdmirYnn0bY9vKG:oIHj1cYFvKEODS1mtNUBk\WyuIHfyc5d1cCCrbjDhJINmdGxidnnhZoltcXS7IHHzd4F6NCCLQ{WwQVIvOjhyNUig{txO	M3;IenNCVkeHUh?=
human QIMR-WIL cell	MVnHdo94fGhiaX7obYJqfGmxbjDhd5NigQ>?		M3jv[mlvcGmkaYTpc44hd2ZiaIXtZY4hWUmPUj3XTWwh[2WubDDndo94fGhiaX6gZUBk\WyuII\pZYJqdGm2eTDhd5NigSxiSVO1NF0zNjJ6N{S0JO69VQ>?	NIfDbWFUSU6JRWK=
human SW1710 cell	NITic4tIem:5dHigbY5pcWKrdHnvckBie3OjeR?=		NGK2[oNKdmirYnn0bY9vKG:oIHj1cYFvKFOZMUexNEBk\WyuIHfyc5d1cCCrbjDhJINmdGxidnnhZoltcXS7IHHzd4F6NCCLQ{WwQVIvOjlzNEKg{txO	M4TyWHNCVkeHUh?=
human SK-UT-1 cell	NX\OdGNJT3Kxd4ToJIlvcGmkaYTpc44h[XO\|YYm=		NHzRZYpKdmirYnn0bY9vKG:oIHj1cYFvKFONLWXUMVEh[2WubDDndo94fGhiaX6gZUBk\WyuII\pZYJqdGm2eTDhd5NigSxiSVO1NF0zNjJ7M{O5JO69VQ>?	M3PDPHNCVkeHUh?=
human IST-SL1 cell	NHTkWJNIem:5dHigbY5pcWKrdHnvckBie3OjeR?=		M2rFVmlvcGmkaYTpc44hd2ZiaIXtZY4hUVOWLWPMNUBk\WyuIHfyc5d1cCCrbjDhJINmdGxidnnhZoltcXS7IHHzd4F6NCCLQ{WwQVIvOzJzN{Sg{txO	MYPTRW5ITVJ?
human SW962 cell	MnXuS5Jwf3SqIHnubIljcXSrb36gZZN{[Xl?		MVrJcohq[mm2aX;uJI9nKGi3bXHuJHNYQTZ{IHPlcIwh\3Kxd4ToJIlvKGFiY3XscEB3cWGkaXzpeJkh[XO\|YYmsJGlEPTB;Mj6zN\|c2PyEQvF2=	M1LMNnNCVkeHUh?=
human EM-2 cell	NHTXNHNIem:5dHigbY5pcWKrdHnvckBie3OjeR?=		MnrTTY5pcWKrdHnvckBw\iCqdX3hckBGVS1{IHPlcIwh\3Kxd4ToJIlvKGFiY3XscEB3cWGkaXzpeJkh[XO\|YYmsJGlEPTB;Mj6zOVM{PyEQvF2=	Mn;nV2FPT0WU
human D-263MG cell	Mn;5S5Jwf3SqIHnubIljcXSrb36gZZN{[Xl?		NWXiT4VsUW6qaXLpeIlwdiCxZjDoeY1idiCGLUK2N21IKGOnbHyg[5Jwf3SqIHnuJIEh[2WubDD2bYFjcWyrdImgZZN{[XluIFnDOVA:Oi5\|OEOyO{DPxE1?	M2HpSHNCVkeHUh?=
human T98G cell	MlXNS5Jwf3SqIHnubIljcXSrb36gZZN{[Xl?		MlXYTY5pcWKrdHnvckBw\iCqdX3hckBVQTiJIHPlcIwh\3Kxd4ToJIlvKGFiY3XscEB3cWGkaXzpeJkh[XO\|YYmsJGlEPTB;Mj6zPFg2PyEQvF2=	MnvyV2FPT0WU
human CTB-1 cell	NY\nOYdOT3Kxd4ToJIlvcGmkaYTpc44h[XO\|YYm=		MW\Jcohq[mm2aX;uJI9nKGi3bXHuJGNVSi1zIHPlcIwh\3Kxd4ToJIlvKGFiY3XscEB3cWGkaXzpeJkh[XO\|YYmsJGlEPTB;Mj6zPVc3OSEQvF2=	NXrNOpZNW0GQR1XS
human Hs-578-T cell	MmPIS5Jwf3SqIHnubIljcXSrb36gZZN{[Xl?		MWDJcohq[mm2aX;uJI9nKGi3bXHuJGh{NTV5OD3UJINmdGxiZ4Lve5RpKGmwIHGgZ4VtdCC4aXHibYxqfHliYYPzZZktKEmFNUC9Nk41OTV6NzFOwG0>	MVvTRW5ITVJ?
human SF126 cell	NGXhdmFIem:5dHigbY5pcWKrdHnvckBie3OjeR?=		MnjnTY5pcWKrdHnvckBw\iCqdX3hckBUTjF{NjDj[YxtKGe{b4f0bEBqdiCjIHPlcIwhfmmjYnnsbZR6KGG\|c3H5MEBKSzVyPUKuOFM3OjFizszN	MYfTRW5ITVJ?
human NCI-H460 cell	NVvEWnFrT3Kxd4ToJIlvcGmkaYTpc44h[XO\|YYm=		Mke0TY5pcWKrdHnvckBw\iCqdX3hckBPS0lvSES2NEBk\WyuIHfyc5d1cCCrbjDhJINmdGxidnnhZoltcXS7IHHzd4F6NCCLQ{WwQVIvPDN7NUWg{txO	NEXTZ\|NUSU6JRWK=
human NCI-H1755 cell	NImzSlBIem:5dHigbY5pcWKrdHnvckBie3OjeR?=		NGn4Xm5KdmirYnn0bY9vKG:oIHj1cYFvKE6FST3INVc2PSClZXzsJIdzd3e2aDDpckBiKGOnbHygeoli[mmuaYT5JIF{e2G7LDDJR\|UxRTJwNUSwOFMh\|ryP	MnnUV2FPT0WU
human HL-60 cell	MojxS5Jwf3SqIHnubIljcXSrb36gZZN{[Xl?		NYK1SG5{UW6qaXLpeIlwdiCxZjDoeY1idiCKTD22NEBk\WyuIHfyc5d1cCCrbjDhJINmdGxidnnhZoltcXS7IHHzd4F6NCCLQ{WwQVIvPTRzNUmg{txO	NHLRbpZUSU6JRWK=
human G-401 cell	M2OyUWdzd3e2aDDpcohq[mm2aX;uJIF{e2G7		M3PnUGlvcGmkaYTpc44hd2ZiaIXtZY4hTy12MEGgZ4VtdCCpcn;3eIghcW5iYTDj[YxtKH[rYXLpcIl1gSCjc4PhfUwhUUN3ME2yMlU3ODl7IN88US=>	MVnTRW5ITVJ?
human AGS cell	MX3Hdo94fGhiaX7obYJqfGmxbjDhd5NigQ>?		MXjJcohq[mm2aX;uJI9nKGi3bXHuJGFIWyClZXzsJIdzd3e2aDDpckBiKGOnbHygeoli[mmuaYT5JIF{e2G7LDDJR\|UxRTJwNU[yOVch\|ryP	Mor1V2FPT0WU
human HuO9 cell	MljKS5Jwf3SqIHnubIljcXSrb36gZZN{[Xl?		MnzTTY5pcWKrdHnvckBw\iCqdX3hckBJfU97IHPlcIwh\3Kxd4ToJIlvKGFiY3XscEB3cWGkaXzpeJkh[XO\|YYmsJGlEPTB;Mj61OlQ2PiEQvF2=	NVfFOIdTW0GQR1XS
human MFE-280 cell	M2OzNWdzd3e2aDDpcohq[mm2aX;uJIF{e2G7		M3\tTGlvcGmkaYTpc44hd2ZiaIXtZY4hVU[HLUK4NEBk\WyuIHfyc5d1cCCrbjDhJINmdGxidnnhZoltcXS7IHHzd4F6NCCLQ{WwQVIvPTZ4OE[g{txO	MlPTV2FPT0WU
human NCI-H292 cell	NEGzO2xIem:5dHigbY5pcWKrdHnvckBie3OjeR?=		MlzjTY5pcWKrdHnvckBw\iCqdX3hckBPS0lvSEK5NkBk\WyuIHfyc5d1cCCrbjDhJINmdGxidnnhZoltcXS7IHHzd4F6NCCLQ{WwQVIvPTd5MkKg{txO	Mn;RV2FPT0WU
human HuO-3N1 cell	NWjGVll4T3Kxd4ToJIlvcGmkaYTpc44h[XO\|YYm=		NF[0XlhKdmirYnn0bY9vKG:oIHj1cYFvKEi3Tz2zUlEh[2WubDDndo94fGhiaX6gZUBk\WyuII\pZYJqdGm2eTDhd5NigSxiSVO1NF0zNjZyM{C3JO69VQ>?	M4HRT3NCVkeHUh?=
human ES3 cell	MnK0S5Jwf3SqIHnubIljcXSrb36gZZN{[Xl?		NEf2PYxKdmirYnn0bY9vKG:oIHj1cYFvKEWVMzDj[YxtKGe{b4f0bEBqdiCjIHPlcIwhfmmjYnnsbZR6KGG\|c3H5MEBKSzVyPUKuOlIzQDVizszN	NUnySIpVW0GQR1XS
human LB2241-RCC cell	NEjBRWtIem:5dHigbY5pcWKrdHnvckBie3OjeR?=		Mn32TY5pcWKrdHnvckBw\iCqdX3hckBNSjJ{NEGtVmNEKGOnbHyg[5Jwf3SqIHnuJIEh[2WubDD2bYFjcWyrdImgZZN{[XluIFnDOVA:Oi54OUC3PUDPxE1?	NILLd4hUSU6JRWK=
human NCI-H1155 cell	M{jxXmdzd3e2aDDpcohq[mm2aX;uJIF{e2G7		NUXIRlJbUW6qaXLpeIlwdiCxZjDoeY1idiCQQ1mtTFEyPTViY3XscEBoem:5dHigbY4h[SClZXzsJJZq[WKrbHn0fUBie3OjeTygTWM2OD1{Lk[5OFA2KM7:TR?=	NELJTJhUSU6JRWK=
human SW872 cell	M1;CO2dzd3e2aDDpcohq[mm2aX;uJIF{e2G7		NHvzc\|hKdmirYnn0bY9vKG:oIHj1cYFvKFOZOEeyJINmdGxiZ4Lve5RpKGmwIHGgZ4VtdCC4aXHibYxqfHliYYPzZZktKEmFNUC9Nk44ODZ5NjFOwG0>	MonmV2FPT0WU
human MHH-ES-1 cell	MY\Hdo94fGhiaX7obYJqfGmxbjDhd5NigQ>?		NGDid\|ZKdmirYnn0bY9vKG:oIHj1cYFvKE2KSD3FV{0yKGOnbHyg[5Jwf3SqIHnuJIEh[2WubDD2bYFjcWyrdImgZZN{[XluIFnDOVA:Oi55Mk[zN{DPxE1?	NXj3[FIxW0GQR1XS
human KYSE-150 cell	M{XPOmdzd3e2aDDpcohq[mm2aX;uJIF{e2G7		M1LySGlvcGmkaYTpc44hd2ZiaIXtZY4hU1mVRT2xOVAh[2WubDDndo94fGhiaX6gZUBk\WyuII\pZYJqdGm2eTDhd5NigSxiSVO1NF0zNjd{OUeg{txO	Mke1V2FPT0WU
human MC-IXC cell	M3TPRWdzd3e2aDDpcohq[mm2aX;uJIF{e2G7		NInIXVdKdmirYnn0bY9vKG:oIHj1cYFvKE2FLVnYR{Bk\WyuIHfyc5d1cCCrbjDhJINmdGxidnnhZoltcXS7IHHzd4F6NCCLQ{WwQVIvQDl3MzFOwG0>	NYX4NVJ{W0GQR1XS
human HCC1187 cell	M3KzeGdzd3e2aDDpcohq[mm2aX;uJIF{e2G7		MXPJcohq[mm2aX;uJI9nKGi3bXHuJGhESzFzOEegZ4VtdCCpcn;3eIghcW5iYTDj[YxtKH[rYXLpcIl1gSCjc4PhfUwhUUN3ME2yMlg6Pjd5IN88US=>	NWfJV2VIW0GQR1XS
human UMC-11 cell	MXHHdo94fGhiaX7obYJqfGmxbjDhd5NigQ>?		MnGyTY5pcWKrdHnvckBw\iCqdX3hckBWVUNvMUGgZ4VtdCCpcn;3eIghcW5iYTDj[YxtKH[rYXLpcIl1gSCjc4PhfUwhUUN3ME2yMlkxPDd5IN88US=>	MVHTRW5ITVJ?
human NB5 cell	M2DiR2dzd3e2aDDpcohq[mm2aX;uJIF{e2G7		MmDXTY5pcWKrdHnvckBw\iCqdX3hckBPSjViY3XscEBoem:5dHigbY4h[SClZXzsJJZq[WKrbHn0fUBie3OjeTygTWM2OD1{LkmzO\|E2KM7:TR?=	NUfYVWZqW0GQR1XS
human A2058 cell	NH;J[49Iem:5dHigbY5pcWKrdHnvckBie3OjeR?=		NHTY[VVKdmirYnn0bY9vKG:oIHj1cYFvKEF{MEW4JINmdGxiZ4Lve5RpKGmwIHGgZ4VtdCC4aXHibYxqfHliYYPzZZktKEmFNUC9Nk46Pzh2NDFOwG0>	MW\TRW5ITVJ?
human Becker cell	NIG3T3JIem:5dHigbY5pcWKrdHnvckBie3OjeR?=		NFHnV3RKdmirYnn0bY9vKG:oIHj1cYFvKEKnY3vldkBk\WyuIHfyc5d1cCCrbjDhJINmdGxidnnhZoltcXS7IHHzd4F6NCCLQ{WwQVMvODFzMUKg{txO	MYXTRW5ITVJ?
human CAS-1 cell	MYTHdo94fGhiaX7obYJqfGmxbjDhd5NigQ>?		NGnZRmdKdmirYnn0bY9vKG:oIHj1cYFvKEODUz2xJINmdGxiZ4Lve5RpKGmwIHGgZ4VtdCC4aXHibYxqfHliYYPzZZktKEmFNUC9N{4xOTV4OTFOwG0>	MnrNV2FPT0WU
human SW780 cell	NWXW[lVNT3Kxd4ToJIlvcGmkaYTpc44h[XO\|YYm=		MV7Jcohq[mm2aX;uJI9nKGi3bXHuJHNYPzhyIHPlcIwh\3Kxd4ToJIlvKGFiY3XscEB3cWGkaXzpeJkh[XO\|YYmsJGlEPTB;Mz6yOVYxQSEQvF2=	NWD1cItnW0GQR1XS
human KM12 cell	NVzxPFZlT3Kxd4ToJIlvcGmkaYTpc44h[XO\|YYm=		MlrsTY5pcWKrdHnvckBw\iCqdX3hckBMVTF{IHPlcIwh\3Kxd4ToJIlvKGFiY3XscEB3cWGkaXzpeJkh[XO\|YYmsJGlEPTB;Mz6zNFE{OiEQvF2=	NXTSXFNFW0GQR1XS
human PC-3 cell	Mn\5S5Jwf3SqIHnubIljcXSrb36gZZN{[Xl?		MlW4TY5pcWKrdHnvckBw\iCqdX3hckBRSy1\|IHPlcIwh\3Kxd4ToJIlvKGFiY3XscEB3cWGkaXzpeJkh[XO\|YYmsJGlEPTB;ND6xO\|QyOSEQvF2=	MnfwV2FPT0WU
human A253 cell	M{HpVWdzd3e2aDDpcohq[mm2aX;uJIF{e2G7		NHywS2lKdmirYnn0bY9vKG:oIHj1cYFvKEF{NUOgZ4VtdCCpcn;3eIghcW5iYTDj[YxtKH[rYXLpcIl1gSCjc4PhfUwhUUN3ME20MlE5QDl\|IN88US=>	Mn;CV2FPT0WU
human NB10 cell	MmPDS5Jwf3SqIHnubIljcXSrb36gZZN{[Xl?		NV7sVWk6UW6qaXLpeIlwdiCxZjDoeY1idiCQQkGwJINmdGxiZ4Lve5RpKGmwIHGgZ4VtdCC4aXHibYxqfHliYYPzZZktKEmFNUC9OE4zOjd5MzFOwG0>	NX\OTYd5W0GQR1XS
human A172 cell	MonTS5Jwf3SqIHnubIljcXSrb36gZZN{[Xl?		NGf5[WhKdmirYnn0bY9vKG:oIHj1cYFvKEFzN{KgZ4VtdCCpcn;3eIghcW5iYTDj[YxtKH[rYXLpcIl1gSCjc4PhfUwhUUN3ME20MlQ1PTdizszN	MnPzV2FPT0WU
human A498 cell	MW\Hdo94fGhiaX7obYJqfGmxbjDhd5NigQ>?		MoC0TY5pcWKrdHnvckBw\iCqdX3hckBCPDl6IHPlcIwh\3Kxd4ToJIlvKGFiY3XscEB3cWGkaXzpeJkh[XO\|YYmsJGlEPTB;ND61OlM5OyEQvF2=	MoDkV2FPT0WU
human SW1573 cell	NVX5NmlGT3Kxd4ToJIlvcGmkaYTpc44h[XO\|YYm=		NVzv[2RQUW6qaXLpeIlwdiCxZjDoeY1idiCVV{G1O\|Mh[2WubDDndo94fGhiaX6gZUBk\WyuII\pZYJqdGm2eTDhd5NigSxiSVO1NF03NjlyNEmxJO69VQ>?	NYPnTlFSW0GQR1XS
human 5637 cell	M4X6T2dzd3e2aDDpcohq[mm2aX;uJIF{e2G7		Mnu2TY5pcWKrdHnvckBw\iCqdX3hckA2PjN5IHPlcIwh\3Kxd4ToJIlvKGFiY3XscEB3cWGkaXzpeJkh[XO\|YYmsJGlEPTB;OD6wO\|kxPCEQvF2=	NGrrToJUSU6JRWK=
human A388 cell	M1\M[Wdzd3e2aDDpcohq[mm2aX;uJIF{e2G7		NVWxdoZkUW6qaXLpeIlwdiCxZjDoeY1idiCDM{i4JINmdGxiZ4Lve5RpKGmwIHGgZ4VtdCC4aXHibYxqfHliYYPzZZktKEmFNUC9NlEvOTN7ODFOwG0>	Ml\lV2FPT0WU
human U251 cell	M1[1Rmdzd3e2aDDpcohq[mm2aX;uJIF{e2G7		MnHtTY5pcWKrdHnvckBw\iCqdX3hckBWOjVzIHPlcIwh\3Kxd4ToJIlvKGFiY3XscEB3cWGkaXzpeJkh[XO\|YYmsJGlEPTB;MkiuNVE4PSEQvF2=	M{Hv[HNCVkeHUh?=

... Click to View More Cell Line Experimental Data

Protocol

Kinase Assay:^[1]	+ Expand Kinase assays: PDK1 is assayed in a direct kinase assay and a coupled assay format measuring PDK1- and PtdIns-3,4-P2-mediated activation of AKT2. For the coupled assay, the final assay mixture (60 μL) contained: 15 mM MOPS, pH 7.2, 1 mg/mL bovine serum albumin, 18 mM β-glycerol phosphate, 0.7 mM dithiothreitol, 3 mM EGTA, 10 mM MgOAc, 7.5 μM ATP, 0.2 μCi of [γ-³³P]ATP, 7.5 μM biotinylated peptide substrate (biotin-ARRRDGGGAQPFRPRAATF), 0.5 μL of PtdIns-3,4-P2-containing phospholipid vesicles, 60 pg of purified recombinant human PDK1, and 172 ng of purified recombinant human AKT2. After incubation for 2 h at room temperature, the biotin-labeled peptide is captured from 10 μl of the assay mixture on streptavidin-coated SPA beads, and product formation is measured by scintillation proximity in a Wallac MicroBeta counter. The product formed is proportional to the time of incubation and to the amount of PDK1 and inactive AKT2 added. PDK1 is added at suboptimal levels so that the assay could sensitively detect inhibitors of AKT2 activation as well as direct inhibitors of PDK1 or AKT2. To measure PDK1 activity directly, the final assay mixture (60 μL) contained 50 mM Tris-HCl, pH 7.5, 0.1 mM EGTA, 0.1 mM EDTA, 0.1% β-mercaptoethanol, 1 mg/mL bovine serum albumin, 10 mM MgOAc, 10 μM ATP, 0.2 μCi of [γ-³³P]ATP, 7.5 μM substrate peptide (H2N-ARRRGVTTKTFCGT), and 60 ng of purified recombinant human PDK1. After 4 h at room temperature, we add 25 mM EDTA and spotted a portion of the reaction mixture on Whatman P81 phosphocellulose paper. The filter paper is washed three times with 0.75% phosphoric acid and once with acetone. After drying, the filter-bound labeled peptide is quantified using a Fuji phosphorimager.
Cell Research:^[1]	+ Expand Cell lines: MDA-468, PC-3, HCT-116 and MiaPaca cells Concentrations: ~10 μM Incubation Time: 72 hours Method: Cells seeded at a low density (1,500–3,000 cells/well, 0.1 mL/well, 96-well plates) are incubated overnight. Compound treatments are made by adding 10 μL/well of the compound in 1% dimethyl sulfoxide and growth medium (final concentration of dimethyl sulfoxide, 0.1%), followed by brief shaking. Treated cells are incubated for 72 hours, and viability is measured by the addition of 10 μL of the metabolic dye WST-1. The WST-1 signal is read in a plate reader at 450 nm, and a no cell, or zero time cell, background is subtracted to calculate the net signal. Results are reported as the average ± S.E. of two or more replicates. (Only for Reference)

Kinase Assay:^[1]

+ Expand

Kinase assays:

PDK1 is assayed in a direct kinase assay and a coupled assay format measuring PDK1- and PtdIns-3,4-P2-mediated activation of AKT2. For the coupled assay, the final assay mixture (60 μL) contained: 15 mM MOPS, pH 7.2, 1 mg/mL bovine serum albumin, 18 mM β-glycerol phosphate, 0.7 mM dithiothreitol, 3 mM EGTA, 10 mM MgOAc, 7.5 μM ATP, 0.2 μCi of [γ-³³P]ATP, 7.5 μM biotinylated peptide substrate (biotin-ARRRDGGGAQPFRPRAATF), 0.5 μL of PtdIns-3,4-P2-containing phospholipid vesicles, 60 pg of purified recombinant human PDK1, and 172 ng of purified recombinant human AKT2. After incubation for 2 h at room temperature, the biotin-labeled peptide is captured from 10 μl of the assay mixture on streptavidin-coated SPA beads, and product formation is measured by scintillation proximity in a Wallac MicroBeta counter. The product formed is proportional to the time of incubation and to the amount of PDK1 and inactive AKT2 added. PDK1 is added at suboptimal levels so that the assay could sensitively detect inhibitors of AKT2 activation as well as direct inhibitors of PDK1 or AKT2. To measure PDK1 activity directly, the final assay mixture (60 μL) contained 50 mM Tris-HCl, pH 7.5, 0.1 mM EGTA, 0.1 mM EDTA, 0.1% β-mercaptoethanol, 1 mg/mL bovine serum albumin, 10 mM MgOAc, 10 μM ATP, 0.2 μCi of [γ-³³P]ATP, 7.5 μM substrate peptide (H2N-ARRRGVTTKTFCGT), and 60 ng of purified recombinant human PDK1. After 4 h at room temperature, we add 25 mM EDTA and spotted a portion of the reaction mixture on Whatman P81 phosphocellulose paper. The filter paper is washed three times with 0.75% phosphoric acid and once with acetone. After drying, the filter-bound labeled peptide is quantified using a Fuji phosphorimager.

Cell Research:^[1]

+ Expand

Cell lines: MDA-468, PC-3, HCT-116 and MiaPaca cells
Concentrations: ~10 μM
Incubation Time: 72 hours
Method: Cells seeded at a low density (1,500–3,000 cells/well, 0.1 mL/well, 96-well plates) are incubated overnight. Compound treatments are made by adding 10 μL/well of the compound in 1% dimethyl sulfoxide and growth medium (final concentration of dimethyl sulfoxide, 0.1%), followed by brief shaking. Treated cells are incubated for 72 hours, and viability is measured by the addition of 10 μL of the metabolic dye WST-1. The WST-1 signal is read in a plate reader at 450 nm, and a no cell, or zero time cell, background is subtracted to calculate the net signal. Results are reported as the average ± S.E. of two or more replicates.
(Only for Reference)

References

Solubility (25°C)

In vitro	DMSO	100 mg/mL (169.07 mM)
	Water	Insoluble
	Ethanol	Insoluble
In vivo	Add solvents to the product individually and in order(Data is from Selleck tests instead of citations): 2% DMSO+30% PEG +2% Tween 80+ddH2O For best results, use promptly after mixing.	4mg/mL

* Please note that Selleck tests the solubility of all compounds in-house, and the actual solubility may differ slightly from published values. This is normal and is due to slight batch-to-batch variations.

Chemical Information Download BX-795 SDF

Molecular Weight	591.47
Formula	C₂₃H₂₆IN₇O₂S
CAS No.	702675-74-9
Storage	3 years -20°C powder
Storage	2 years -80°C in solvent
Synonyms	N/A

Bio Calculators

Molarity Calculator

Calculate the mass, volume or concentration required for a solution. The Selleck molarity calculator is based on the following equation:

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

*When preparing stock solutions, please always use the batch-specific molecular weight of the product found on the via label and MSDS / COA (available on product pages).

Dilution Calculator

Calculate the dilution required to prepare a stock solution. The Selleck dilution calculator is based on the following equation:

Concentration _(start) x Volume _(start) = Concentration _(final) x Volume _(final)

This equation is commonly abbreviated as: C1V1 = C2V2 ( Input Output )

* When preparing stock solutions always use the batch-specific molecular weight of the product found on the vial label and MSDS / COA (available online).

The Serial Dilution Calculator Equation

Serial Dilutions
Concertration (start):
Dilution-folds:

Computed Result

C1=C0/X	C1:	LOG(C1):
C2=C1/X	C2:	LOG(C2):
C3=C2/X	C3:	LOG(C3):
C4=C3/X	C4:	LOG(C4):
C5=C4/X	C5:	LOG(C5):
C6=C5/X	C6:	LOG(C6):
C7=C6/X	C7:	LOG(C7):
C8=C7/X	C8:	LOG(C8):

Molecular Weight Calculator

Enter the chemical formula of a compound to calculate its molar mass and elemental composition:

Tip: Chemical formula is case sensitive. C10H16N2O2 c10h16n2o2

Instructions to calculate molar mass (molecular weight) of a chemical compound:

To calculate molar mass of a chemical compound, please enter its chemical formula and click 'Calculate'.

Definitions of molecular mass, molecular weight, molar mass and molar weight:

Molecular mass (molecular weight) is the mass of one molecule of a substance and is expressed in the unified atomic mass units (u). (1 u is equal to 1/12 the mass of one atom of carbon-12)
Molar mass (molar weight) is the mass of one mole of a substance and is expressed in g/mol.

Molarity Calculator

Tech Support

Answers to questions you may have can be found in the inhibitor handling instructions. Topics include how to prepare stock solutions, how to store inhibitors, and issues that need special attention for cell-based assays and animal experiments.

Handling Instructions

Tel: +1-832-582-8158 Ext:3

If you have any other enquiries, please leave a message.

Frequently Asked Questions

Question 1:
Can you suggest an in vivo formulation of S1274 for animal studies?
Answer:
We recommend to use the vehicle 2% DMSO+30% PEG +2% Tween 80+ddH2O for in vivo study.

PDK Signaling Pathway Map

Related PDK Products0

CHIR-99021 (CT99021) ^New

CHIR-99021 (CT99021) is a GSK-3α and GSK-3β inhibitor with IC50 of 10 nM and 6.7 nM, respectively. CHIR99201 does not exhibit cross-reactivity against cyclin-dependent kinases (CDKs) and shows a 350-fold selectivity toward GSK-3β compared to CDKs.
Dorsomorphin (Compound C) ^New

Dorsomorphin is a potent, reversible, selective AMPK inhibitor with K_i of 109 nM in cell-free assays, exhibiting no significant inhibition of several structurally related kinases including ZAPK, SYK, PKCθ, PKA, and JAK3. Also inhibits type I BMP receptor activity.
MHY1485 ^New

MHY1485 is a potent, and cell-permeable mTOR activator, and also potently inhibits autophagy.
OSU-03012 (AR-12)

OSU-03012 (AR-12) is a potent inhibitor of recombinant PDK-1(phosphoinositide-dependent kinase 1) with IC50 of 5 μM in a cell-free assay and 2-fold increase in potency over OSU-02067.

Features:A derivative of celecoxib with 10-fold greater antitumor activity, but lacks celecoxib's COX-2 inhibitory activity.
BX-912

BX912 is a potent and specific PDK1 inhibitor with IC50 of 12 nM, 9- and 105- fold greater selectivity for PDK1 than PKA and PKC in cell-free assays, respectively. In comparison to GSK3β, selectivity for PDK1 is 600-fold.
GSK2334470

GSK2334470 is a novel PDK1 inhibitor with IC50 of ~10 nM in a cell-free assay, with no activity at other close related AGC-kinases.
Rapamycin (Sirolimus)

Rapamycin (Sirolimus) is a specific mTOR inhibitor with IC50 of ~0.1 nM HEK293 cells.
MK-2206 2HCl

MK-2206 2HCl is a highly selective inhibitor of Akt1/2/3 with IC50 of 8 nM/12 nM/65 nM in cell-free assays, respectively; no inhibitory activities against 250 other protein kinases observed. Phase 2.

Features:The first allosteric small molecule inhibitor of Akt to enter clinical development.
CHIR-99021 (CT99021) HCl

CHIR-99021 HCl (CT99021) is hydrochloride of CHIR-99021, which is a GSK-3α/β inhibitor with IC50 of 10 nM/6.7 nM; CHIR-99021 shows greater than 500-fold selectivity for GSK-3 versus its closest homologs Cdc2 and ERK2.
LY294002

LY294002 is the first synthetic molecule known to inhibit PI3Kα/δ/β with IC50 of 0.5 μM/0.57 μM/0.97 μM, respectively; more stable in solution than Wortmannin, and also blocks autophagosome formation. It not only binds to class I PI3Ks and other PI3K-related kinases, but also to novel targets seemingly unrelated to the PI3K family.

Choose Your Country or Region

By Signaling Pathways

By product type

BX-795

Cited by 10 Publications

4 Customer Reviews

Purity & Quality Control

Choose Selective PDK Inhibitors

Biological Activity

Protocol

References

Solubility (25°C)

Chemical Information Download BX-795 SDF

Bio Calculators

Molarity Calculator

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

Dilution Calculator

Concentration _(start) x Volume _(start) = Concentration _(final) x Volume _(final)

The Serial Dilution Calculator Equation

Serial Dilutions

Computed Result

Molecular Weight Calculator

Total Molecular Weight: g/mol

Instructions to calculate molar mass (molecular weight) of a chemical compound:

Definitions of molecular mass, molecular weight, molar mass and molar weight:

Molarity Calculator

Tech Support

Frequently Asked Questions

PDK Signaling Pathway Map

Related PDK Products0

Choose Your Country or Region

By Signaling Pathways

By product type

BX-795

Cited by 10 Publications

4 Customer Reviews

Purity & Quality Control

Choose Selective PDK Inhibitors

Biological Activity

Protocol

References

Solubility (25°C)

Chemical Information Download BX-795 SDF

Bio Calculators

Molarity Calculator

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

Dilution Calculator

Concentration (start) x Volume (start) = Concentration (final) x Volume (final)

The Serial Dilution Calculator Equation

Serial Dilutions

Computed Result

Molecular Weight Calculator

Total Molecular Weight: g/mol

Instructions to calculate molar mass (molecular weight) of a chemical compound:

Definitions of molecular mass, molecular weight, molar mass and molar weight:

Molarity Calculator

Tech Support

Frequently Asked Questions

PDK Signaling Pathway Map

Related PDK Products0

Concentration _(start) x Volume _(start) = Concentration _(final) x Volume _(final)